melanocortin is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-15. Numbers and descriptions here follow the published literature rather than marketing material.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic cyclic heptapeptide | Alpha-MSH analogue containing a D-phenylalanine residue |
| Molecular formula | C50H69N15O9 | Average molecular mass approximately 1024.2 g/mol |
| Appearance | White to off-white lyophilised powder | Normally supplied as a freeze-dried solid in a sealed vial |
| Solubility | Freely soluble in water and polar solvents | Dissolves readily in aqueous buffers and in alcohol-water mixtures |
| Receptor targets | MC1R, MC3R, MC4R, MC5R | Acts as a non-selective melanocortin receptor agonist |
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
== Perinatal environment == Autism is associated with some perinatal and obstetric conditions. Infants that are born pre-term often have various neurodevelopmental impairments related to motor skills, cognition, receptive and expressive language, and socio-emotional capabilities. Pre-term infants are also at a higher risk of having various neurodevelopmental disorders such as cerebral palsy and autism, as well as psychiatric disorders related to attention, anxiety, and impaired social communication. It has also been proposed that the functions of the hypothalamic-pituitary-adrenal axis and brain connectivity in pre-term infants may be affected by NICU-related stress resulting in deficits in emotional regulation and socio-emotional capabilities. A 2019 analysis of perinatal and neonatal risk factors found that autism was associated with abnormal fetal positioning, umbilical cord complications, low 5-minute Apgar score, low birth weight and gestation duration, fetal distress, meconium aspiration syndrome, trauma or injury during birth, maternal hemorrhaging, multiple birth, feeding disorders, neonatal anemia, birth defects/malformation, incompatibility with maternal blood type, and jaundice/hyperbilirubinemia. These associations do not denote a causal relationship for any individual factor. There is growing evidence that perinatal exposure to air pollution may be a risk factor for autism, although this evidence has methodological limitations, including a small number of studies and failure to control for potential confounding factors.
== Epidemiology == The incidence and prevalence of PMD are unknown, and no studies have yet investigated its prevalence or incidence. However, it is generally agreed that PMD is a very rare condition. Some uncertainty regarding the incidence of PMD may be attributed to its confusion with keratoconus. PMD is not linked to race or age, although most cases present early in life, between 20 and 40 years of age. While PMD is usually considered to affect men and women equally, some studies suggest that it may affect men more frequently. Several diseases have been observed in people with PMD. However, no causal relationships have been established between any of the associated diseases and the pathogenesis of PMD. Such diseases include: chronic open angle glaucoma, retinitis pigmentosa, retinal lattice degeneration, scleroderma, kerato-conjunctivitis, eczema, and hyperthyroidism.
=== Tourne === Compared to malic and citric acids, tartaric acid is usually considered microbiologically stable. However, some species of Lactobacillus (particularly L. brevis and L. plantarum) have the potential to degrade tartaric acid in wine, reducing a wine's total acidity by 3-50%. French winemakers had long observed this phenomenon and called it tourne (meaning "turn to brown") in reference to the color change that can occur in the wine at the same time likely due to other processes at work in addition to the tartaric loss. While Lactobacillus is the most common culprit of tourne, some species of the spoilage film yeast Candida can also metabolize tartaric acid.
Besides the potential newer effects as antibiotics or anti-cancers, P.arhizus has traditionally been used for wound healing and hemorragic disorders in places such as Italy and regions of Africa. Looking beyond the composition of P.arhizus, the species has a number of confirmed uses as well as theoretical potentials. A traditional use of the fungus is as a dyeing agent (hence "dyeball") of assorted textiles, producing a range of pigments varying in description from yellow to shades of brown. P.arhizus has also has been mentioned for its use in forestry and land restoration as a mycorrhizal agent for inoculation projects, and some online gardening websites mention its positive effects on plant performance.
Sources: en.wikipedia.org
=== Intracrines and regenerative Medicine === The discovery of intracrine loops in stem cell regulation has profound implications for regenerative medicine. Because intracrines can establish long-lasting differentiation programs, they offer potential therapeutic targets for tissue regeneration and repair. For example, in cardiac repair, HMGB1 has been shown to enhance the proliferation and differentiation of cardiac stem cells following myocardial infarction, suggesting that modulating intracrine pathways could improve heart regeneration. The ability of certain intracrines to reprogram cells into pluripotent-like states also opens new avenues for regenerative therapies. Oct3/4, Sox2, and Nanog, all of which are involved in maintaining stem cell pluripotency, can potentially be introduced into cells to drive reprogramming without the need for genetic modification. This approach could provide safer and more controlled methods for generating patient-specific stem cells.
RU-24213, also known as 3-hydroxy-N-propyl-N-(phenylethyl)phenethylamine, is a dopamine receptor agonist of the phenethylamine family related to dopamine. It is a selective dopamine D2-like receptor agonist. Subsequently, however, RU-24213 was found to also act as a potent κ-opioid receptor (KOR) antagonist. It led to the development of the diphenylethylamine series of KOR ligands. RU-24213 was first described in the scientific literature in 1978.
Usually, PMR only affects adults over the age of 50. The average age of a person who has PMR is about 70 years old, with the highest prevalence in those older than 70. Women are three times as likely to get PMR as men. People of Western and Northern European descent are more likely to get this disease. It is more likely to affect people of Northern European origin; Scandinavians are especially vulnerable. About 50% of people with temporal arteritis also have polymyalgia rheumatica.
== Lipid transportation == Due to the hydrophobic nature of membrane lipids, triglycerides and cholesterol, they require special transport proteins known as lipoproteins. The amphipathic structure of lipoproteins allows the triglycerides and cholesterol to be transported through the blood. Chylomicrons are one sub-group of lipoproteins which carry the digested lipids from small intestine to the rest of the body. The varying densities between the types of lipoproteins are characteristic to what type of fats they transport. For example, very-low-density lipoproteins (VLDL) carry the triglycerides synthesized by our body and low-density lipoproteins (LDL) transport cholesterol to our peripheral tissues. A number of these lipoproteins are synthesized in the liver, but not all of them originate from this organ.
== Centenarians in antiquity == While the number of centenarians per capita was much lower in ancient times than today, the data suggest that they were not unheard of. Estimates of life expectancy in antiquity are far lower than modern values largely due to the far greater incidence of deaths in infancy or childhood, though adult mortality was also considerably greater than today. The assumption of what constitutes "old age", or being "elderly", at least, seems to have remained unchanged since antiquity, the line being generally drawn at either sixty or sixty-five years; Psalm 90:10 in the Hebrew Bible appears to give seventy to eighty years as the natural life expectancy of a person surviving into old age, "The years of our life are seventy, or even by reason of strength eighty". A survey of the lifespans of male individuals with entries in the Oxford Classical Dictionary (i.e., a sample pre-selected to include those who lived long enough to attain historical notability) found a median lifespan of 72 years, and a range of 32 to 107 years, for 128 individuals born before 100 BC (though the same study found a median lifespan of 66 years for 100 individuals born after 100 BC but no later than 602 AD); by comparison, male individuals listed in Chambers Biographical Dictionary who died between 1900 and 1949 had a median lifespan of 71.5 years, with a range between 29 and 105 years. But as indicated above, far fewer in antiquity survived even from early adulthood to such advanced age – probably under a fifth, compared to a global average of two-thirds today.
Sources: en.wikipedia.org
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.
No approved regulatory indication exists in major markets. An approval exists for a different peptide, afamelanotide, which is used for a rare photosensitivity disorder called erythropoietic protoporphyria. Melanotan-2 itself remains a research compound with no cleared clinical role.
Melanocortin-1 receptors on melanocytes are the receptor most closely linked to pigment production. The peptide is not selective, however, and also activates melanocortin-3, melanocortin-4, and melanocortin-5 receptors. That lack of selectivity is the usual explanation offered for both its range of observed effects and its off-target effects.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.